IMMUNOGENICITY OF 2 DOSES OF YEAST RECOMBINANT HEPATITIS-B VACCINE INHEALTHY OLDER ADULTS

To determine the immunogenicity of two doses of yeast recombinant hepa titis B virus (HBV) vaccine containing surface (S) protein, an open-la bel, multicenter trial was conducted in 199 healthy HBV-seronegative a dults greater than or equal to 40 years old. Volunteers were randomly assigned to 1 of 5 groups to receive a total of three 10-mu g doses, a t 0, 1, and 6 months, or a total of two doses of 20 mu g and 10 mu g, 20 mu g and 20 mu g, 40 mu g and 10 mu g, or 40 mu g and 20 mu g at 0 and 6 months. The 40-mu/20-mu g regimen elicited the highest rate of s eroprotection (96.2%), with a geometric mean titer of antibody against the S protein of 369 mIU/mL, not significantly different from the 536 mIU/mL achieved with three doses, These results suggest that a two-do se regimen can achieve seroprotection similar to that of the three-dos e regimen. Whether a shorter interval can be used or a booster dose wi ll be needed later to confer durable immunity are unknown.